Derek A O'Reilly

Closest collaborators

The 25 strongest of 67 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

1. Juan W. Valle · 8 shared papers, 2017–2023 · strength 0.70
   • Paper The assessment of pancreatic exocrine function in patients with inoperable pancreatic cancer: In need of a new gold-sta… DOI 10.1016/j.pan.2020.03.020↗
   • Paper Immediate surgery compared with short-course neoadjuvant gemcitabine plus capecitabine, FOLFIRINOX, or chemoradiotherap… DOI 10.1016/s2468-1253(22)00348-x↗
   • Paper The Influence of Patients' Age on the Outcome of Treatment for Pancreatic Ductal Adenocarcinoma. DOI 10.1097/mpa.0000000000001486↗
2. Claus Jørgensen · 3 shared papers, 2022–2026 · strength 0.49
   • Paper A ternary association of KRas, EphA2, and integrins controls PDAC cell behavior. DOI 10.1016/j.jbc.2026.113421↗
   • Paper Pancreatic ductal adenocarcinoma cells employ integrin α6β4 to form hemidesmosomes and regulate cell proliferation. DOI 10.1016/j.matbio.2022.03.010↗
   • Paper A microenvironment-inspired synthetic three-dimensional model for pancreatic ductal adenocarcinoma organoids. DOI 10.1038/s41563-021-01085-1↗
3. Jonathan D. Humphries · 3 shared papers, 2022–2026 · strength 0.49
   • Paper A ternary association of KRas, EphA2, and integrins controls PDAC cell behavior. DOI 10.1016/j.jbc.2026.113421↗
   • Paper Pancreatic ductal adenocarcinoma cells employ integrin α6β4 to form hemidesmosomes and regulate cell proliferation. DOI 10.1016/j.matbio.2022.03.010↗
   • Paper A microenvironment-inspired synthetic three-dimensional model for pancreatic ductal adenocarcinoma organoids. DOI 10.1038/s41563-021-01085-1↗
4. Martin James Humphries · 3 shared papers, 2022–2026 · strength 0.49
   • Paper A ternary association of KRas, EphA2, and integrins controls PDAC cell behavior. DOI 10.1016/j.jbc.2026.113421↗
   • Paper Pancreatic ductal adenocarcinoma cells employ integrin α6β4 to form hemidesmosomes and regulate cell proliferation. DOI 10.1016/j.matbio.2022.03.010↗
   • Paper A microenvironment-inspired synthetic three-dimensional model for pancreatic ductal adenocarcinoma organoids. DOI 10.1038/s41563-021-01085-1↗
5. Neil Bibby · 2 shared papers, 2020–2023 · strength 0.44
   • Paper From prehab to rehab: Nutritional support for people undergoing pancreatic cancer surgery. DOI 10.1111/jhn.13040↗
   • Paper The assessment of pancreatic exocrine function in patients with inoperable pancreatic cancer: In need of a new gold-sta… DOI 10.1016/j.pan.2020.03.020↗
6. Mairead Geraldine McNamara · 4 shared papers, 2018–2020 · strength 0.42
   • Paper The assessment of pancreatic exocrine function in patients with inoperable pancreatic cancer: In need of a new gold-sta… DOI 10.1016/j.pan.2020.03.020↗
   • Paper The Influence of Patients' Age on the Outcome of Treatment for Pancreatic Ductal Adenocarcinoma. DOI 10.1097/mpa.0000000000001486↗
   • Paper Irreversible Electroporation in pancreatic ductal adenocarcinoma: Is there a role in conjunction with conventional trea… DOI 10.1016/j.ejso.2018.07.047↗
7. John P. Neoptolemos · 5 shared papers, 2017–2023 · strength 0.35
   • Paper Immediate surgery compared with short-course neoadjuvant gemcitabine plus capecitabine, FOLFIRINOX, or chemoradiotherap… DOI 10.1016/s2468-1253(22)00348-x↗
   • Paper The Impact of Positive Resection Margins on Survival and Recurrence Following Resection and Adjuvant Chemotherapy for P… DOI 10.1097/sla.0000000000002557↗
   • Paper Diagnosis and management of pancreatic cancer in adults: A summary of guidelines from the UK National Institute for Hea… DOI 10.1016/j.pan.2018.09.012↗
8. Nicola de Liguori Carino · 3 shared papers, 2018–2022 · strength 0.34
   • Paper A fast-track surgery programme leads to timelier treatment and higher resection rates in pancreatic cancer. DOI 10.1016/j.hpb.2021.10.019↗
   • Paper The Influence of Patients' Age on the Outcome of Treatment for Pancreatic Ductal Adenocarcinoma. DOI 10.1097/mpa.0000000000001486↗
   • Paper Irreversible Electroporation in pancreatic ductal adenocarcinoma: Is there a role in conjunction with conventional trea… DOI 10.1016/j.ejso.2018.07.047↗
9. Ajith Kumar Siriwardena · 3 shared papers, 2018–2022 · strength 0.34
   • Paper A fast-track surgery programme leads to timelier treatment and higher resection rates in pancreatic cancer. DOI 10.1016/j.hpb.2021.10.019↗
   • Paper The Influence of Patients' Age on the Outcome of Treatment for Pancreatic Ductal Adenocarcinoma. DOI 10.1097/mpa.0000000000001486↗
   • Paper Irreversible Electroporation in pancreatic ductal adenocarcinoma: Is there a role in conjunction with conventional trea… DOI 10.1016/j.ejso.2018.07.047↗
10. Ángela Lamarca · 3 shared papers, 2019–2020 · strength 0.33
    • Paper The assessment of pancreatic exocrine function in patients with inoperable pancreatic cancer: In need of a new gold-sta… DOI 10.1016/j.pan.2020.03.020↗
    • Paper The Influence of Patients' Age on the Outcome of Treatment for Pancreatic Ductal Adenocarcinoma. DOI 10.1097/mpa.0000000000001486↗
    • Paper Identification of patients with pancreatic adenocarcinoma due to inheritable mutation: Challenges of daily clinical pra… DOI 10.4251/wjgo.v11.i2.102↗
11. Paula Ghaneh · 4 shared papers, 2017–2023 · strength 0.29
    • Paper Immediate surgery compared with short-course neoadjuvant gemcitabine plus capecitabine, FOLFIRINOX, or chemoradiotherap… DOI 10.1016/s2468-1253(22)00348-x↗
    • Paper The Impact of Positive Resection Margins on Survival and Recurrence Following Resection and Adjuvant Chemotherapy for P… DOI 10.1097/sla.0000000000002557↗
    • Paper Patterns of Recurrence After Resection of Pancreatic Ductal Adenocarcinoma: A Secondary Analysis of the ESPAC-4 Randomi… DOI 10.1001/jamasurg.2019.3337↗
12. Markus Wolfgang Büchler · 4 shared papers, 2017–2023 · strength 0.29
    • Paper Immediate surgery compared with short-course neoadjuvant gemcitabine plus capecitabine, FOLFIRINOX, or chemoradiotherap… DOI 10.1016/s2468-1253(22)00348-x↗
    • Paper The Impact of Positive Resection Margins on Survival and Recurrence Following Resection and Adjuvant Chemotherapy for P… DOI 10.1097/sla.0000000000002557↗
    • Paper Patterns of Recurrence After Resection of Pancreatic Ductal Adenocarcinoma: A Secondary Analysis of the ESPAC-4 Randomi… DOI 10.1001/jamasurg.2019.3337↗
13. Daniel H. Palmer · 4 shared papers, 2017–2023 · strength 0.29
    • Paper Immediate surgery compared with short-course neoadjuvant gemcitabine plus capecitabine, FOLFIRINOX, or chemoradiotherap… DOI 10.1016/s2468-1253(22)00348-x↗
    • Paper The Impact of Positive Resection Margins on Survival and Recurrence Following Resection and Adjuvant Chemotherapy for P… DOI 10.1097/sla.0000000000002557↗
    • Paper Patterns of Recurrence After Resection of Pancreatic Ductal Adenocarcinoma: A Secondary Analysis of the ESPAC-4 Randomi… DOI 10.1001/jamasurg.2019.3337↗
14. Christopher Michael Halloran · 4 shared papers, 2017–2023 · strength 0.29
    • Paper Immediate surgery compared with short-course neoadjuvant gemcitabine plus capecitabine, FOLFIRINOX, or chemoradiotherap… DOI 10.1016/s2468-1253(22)00348-x↗
    • Paper The Impact of Positive Resection Margins on Survival and Recurrence Following Resection and Adjuvant Chemotherapy for P… DOI 10.1097/sla.0000000000002557↗
    • Paper Patterns of Recurrence After Resection of Pancreatic Ductal Adenocarcinoma: A Secondary Analysis of the ESPAC-4 Randomi… DOI 10.1001/jamasurg.2019.3337↗
15. Mahak Fatima · 1 shared paper, 2026 · strength 0.26
    • Paper A ternary association of KRas, EphA2, and integrins controls PDAC cell behavior. DOI 10.1016/j.jbc.2026.113421↗
16. Saurabh Jamdar · 2 shared papers, 2020–2022 · strength 0.25
    • Paper A fast-track surgery programme leads to timelier treatment and higher resection rates in pancreatic cancer. DOI 10.1016/j.hpb.2021.10.019↗
    • Paper The Influence of Patients' Age on the Outcome of Treatment for Pancreatic Ductal Adenocarcinoma. DOI 10.1097/mpa.0000000000001486↗
17. Thomas Satyadas · 2 shared papers, 2020–2022 · strength 0.25
    • Paper A fast-track surgery programme leads to timelier treatment and higher resection rates in pancreatic cancer. DOI 10.1016/j.hpb.2021.10.019↗
    • Paper The Influence of Patients' Age on the Outcome of Treatment for Pancreatic Ductal Adenocarcinoma. DOI 10.1097/mpa.0000000000001486↗
18. Christopher Below · 2 shared papers, 2022 · strength 0.24
    • Paper Pancreatic ductal adenocarcinoma cells employ integrin α6β4 to form hemidesmosomes and regulate cell proliferation. DOI 10.1016/j.matbio.2022.03.010↗
    • Paper A microenvironment-inspired synthetic three-dimensional model for pancreatic ductal adenocarcinoma organoids. DOI 10.1038/s41563-021-01085-1↗
19. Yuk Ting Ma · 3 shared papers, 2017–2023 · strength 0.22
    • Paper Immediate surgery compared with short-course neoadjuvant gemcitabine plus capecitabine, FOLFIRINOX, or chemoradiotherap… DOI 10.1016/s2468-1253(22)00348-x↗
    • Paper Patterns of Recurrence After Resection of Pancreatic Ductal Adenocarcinoma: A Secondary Analysis of the ESPAC-4 Randomi… DOI 10.1001/jamasurg.2019.3337↗
    • Paper Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic c… DOI 10.1016/s0140-6736(16)32409-6↗
20. Paul J. Ross · 3 shared papers, 2017–2023 · strength 0.22
    • Paper Immediate surgery compared with short-course neoadjuvant gemcitabine plus capecitabine, FOLFIRINOX, or chemoradiotherap… DOI 10.1016/s2468-1253(22)00348-x↗
    • Paper Patterns of Recurrence After Resection of Pancreatic Ductal Adenocarcinoma: A Secondary Analysis of the ESPAC-4 Randomi… DOI 10.1001/jamasurg.2019.3337↗
    • Paper Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic c… DOI 10.1016/s0140-6736(16)32409-6↗
21. Thilo Hackert · 3 shared papers, 2017–2023 · strength 0.22
    • Paper Immediate surgery compared with short-course neoadjuvant gemcitabine plus capecitabine, FOLFIRINOX, or chemoradiotherap… DOI 10.1016/s2468-1253(22)00348-x↗
    • Paper Patterns of Recurrence After Resection of Pancreatic Ductal Adenocarcinoma: A Secondary Analysis of the ESPAC-4 Randomi… DOI 10.1001/jamasurg.2019.3337↗
    • Paper Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic c… DOI 10.1016/s0140-6736(16)32409-6↗
22. David Cunningham · 3 shared papers, 2017–2023 · strength 0.22
    • Paper Immediate surgery compared with short-course neoadjuvant gemcitabine plus capecitabine, FOLFIRINOX, or chemoradiotherap… DOI 10.1016/s2468-1253(22)00348-x↗
    • Paper Patterns of Recurrence After Resection of Pancreatic Ductal Adenocarcinoma: A Secondary Analysis of the ESPAC-4 Randomi… DOI 10.1001/jamasurg.2019.3337↗
    • Paper Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic c… DOI 10.1016/s0140-6736(16)32409-6↗
23. Harpreet Singh Wasan · 3 shared papers, 2017–2023 · strength 0.22
    • Paper Immediate surgery compared with short-course neoadjuvant gemcitabine plus capecitabine, FOLFIRINOX, or chemoradiotherap… DOI 10.1016/s2468-1253(22)00348-x↗
    • Paper Patterns of Recurrence After Resection of Pancreatic Ductal Adenocarcinoma: A Secondary Analysis of the ESPAC-4 Randomi… DOI 10.1001/jamasurg.2019.3337↗
    • Paper Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic c… DOI 10.1016/s0140-6736(16)32409-6↗
24. Richard A Hubner · 2 shared papers, 2019–2020 · strength 0.19
    • Paper The Influence of Patients' Age on the Outcome of Treatment for Pancreatic Ductal Adenocarcinoma. DOI 10.1097/mpa.0000000000001486↗
    • Paper Identification of patients with pancreatic adenocarcinoma due to inheritable mutation: Challenges of daily clinical pra… DOI 10.4251/wjgo.v11.i2.102↗
25. Rille Pihlak · 2 shared papers, 2018–2019 · strength 0.18
    • Paper Irreversible Electroporation in pancreatic ductal adenocarcinoma: Is there a role in conjunction with conventional trea… DOI 10.1016/j.ejso.2018.07.047↗
    • Paper Identification of patients with pancreatic adenocarcinoma due to inheritable mutation: Challenges of daily clinical pra… DOI 10.4251/wjgo.v11.i2.102↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.